Pedro Aguiar1, Auro Del Giglio2, Luke Alastair Perry3, Jahan Penny-Dimri3, Hani Babiker4, Hakaru Tadokoro5, Gilberto Lopes6, Ramon Andrade De Mello7,8. 1. Doutorando, Faculdade de Medicina do ABC, Santo André, SP, Brazil. 2. Centro de Estudos e Pesquisa de Hematologia e Oncologia, Faculdade de Medicina do ABC, Santo André, SP, Brazil. 3. Graduando, Monash University, Australia. 4. Statician, Honor Health Scottsdale, AZ 85260, USA. 5. Setor de Oncologia Clínica, Universidade Federal de São Paulo, São Paulo, SP, Brazil. 6. Global Oncology Chair, Sylvester Comprehensive Cancer Center at the University of Miami, USA. 7. Research Centre/Department of Medical Oncology, Oncology and Hematology Nucleus of Ceará (NOHC), Fortaleza, CE, Brazil. 8. Department of Biomedical Sciences & Medicine, University of Algarve, Faro, Portugal/Algarve Biomedical Centre, University of Algarve, Faro, Portugal.
Abstract
AIM: Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation. METHODS: The number of patients with non-small-cell lung cancer eligible for immunotherapy was estimated using local epidemiology data. We extracted survival data from RCTs to estimate the life-years saved in a 5-year time horizon. All costs were in local prices converted to US dollars. RESULTS: In the first-line, the budget impact of pembrolizumab decreased by 35% through risk-sharing. In the second-line, patient selection by programmed-death receptor ligand 1 expression decreased the budgetary impact by 45%, and improved cost-effectiveness. Immunotherapy was more cost-effective in the first-line. CONCLUSION: Given current pricing, Immune checkpoint inhibitors are cost-prohibitive in the majority of South American health services. Nevertheless, several strategies should improve access to immunotherapy.
AIM: Immune checkpoint inhibitors revolutionized the treatment of non-small-cell lung cancer, although their costs are a limitation. METHODS: The number of patients with non-small-cell lung cancer eligible for immunotherapy was estimated using local epidemiology data. We extracted survival data from RCTs to estimate the life-years saved in a 5-year time horizon. All costs were in local prices converted to US dollars. RESULTS: In the first-line, the budget impact of pembrolizumab decreased by 35% through risk-sharing. In the second-line, patient selection by programmed-death receptor ligand 1 expression decreased the budgetary impact by 45%, and improved cost-effectiveness. Immunotherapy was more cost-effective in the first-line. CONCLUSION: Given current pricing, Immune checkpoint inhibitors are cost-prohibitive in the majority of South American health services. Nevertheless, several strategies should improve access to immunotherapy.
Entities:
Keywords:
global oncology; health policy; immunotherapy; pharmacoeconomics
Authors: Eduardo Edelman Saul; Raquel B Guerra; Michelle Edelman Saul; Laercio Lopes da Silva; Gabriel F P Aleixo; Raquel M K Matuda; Gilberto Lopes Journal: Nat Cancer Date: 2020-11-30
Authors: Ramon Andrade De Mello; Jin-Hui Zhu; Jairo Iavelberg; Artur Henrique Potim; Débora Simonetti; José Antônio Silva; Pedro Castelo-Branco; Daniel Humberto Pozza; Carla Chizuru Tajima; Maria Tolia; Georgio Antoniou Journal: Transl Lung Cancer Res Date: 2020-12